STOCK TITAN
  1. Home
  2. News
  3. VYGR

Voyager Therapeutics Inc - VYGR STOCK NEWS

Welcome to our dedicated news page for Voyager Therapeutics (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Voyager Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Voyager Therapeutics's position in the market.

News
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Rhea-AI Summary
Voyager Therapeutics, in collaboration with Neurocrine Biosciences, selects a lead development candidate for the GBA1 gene therapy program to treat Parkinson's disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with a novel capsid. Voyager expects a $3 million milestone payment and potential future payments based on program advancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
News
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Voyager Therapeutics, Inc. grants non-qualified stock options and restricted stock units to Dr. Toby Ferguson as an inducement for his employment. The stock option allows the purchase of 210,000 shares at $9.26 per share, while the restricted stock unit represents 105,000 shares. Both awards vest over several years, contingent on Dr. Ferguson's continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
News
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
Rhea-AI Summary
Voyager Therapeutics, Inc. appoints Toby Ferguson, M.D., Ph.D., as Chief Medical Officer, bringing valuable expertise in advancing clinical programs for neurological diseases. Ferguson's track record includes successful IND filings and proof-of-concept clinical trials, enhancing Voyager's prospects for developing neurogenetic medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
management
News
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Rhea-AI Summary
Voyager Therapeutics, Inc. reported strong financial results for Q4 2023 and full year 2023, with approximately $431 million in pro-forma cash as of December 31, 2023. The company achieved key milestones, including strategic collaborations with Novartis and Neurocrine Biosciences. Voyager expects to advance multiple programs into the clinic by the end of next year, with a focus on gene therapy programs for diseases like Alzheimer's and ALS. The company's cash position and anticipated milestones provide runway into 2027, supporting the generation of clinical data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.25%
Tags
earnings
-
News
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
Rhea-AI Summary
Voyager Therapeutics, Inc. announces the selection of a lead development candidate in the Friedreich’s ataxia program in collaboration with Neurocrine Biosciences. The candidate combines a frataxin gene replacement payload with a novel capsid derived from Voyager’s TRACER platform. The program is expected to enter first-in-human clinical trials in 2025, triggering a $5 million milestone payment to Voyager. Voyager could receive additional milestone payments based on program advancement. The strategic collaboration aims to address the challenging FA disease through gene therapy, with potential milestone payments of up to $1.3 billion for Voyager.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
none
-
News
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) will report Q4 2023 financial results on Feb 28, 2024. A conference call and webcast will follow to review the results. Participants can register in advance to join the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
earnings
News
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced new data on VY-TAU01, their lead anti-tau antibody, and tau silencing gene therapy program for Alzheimer's disease treatment. The data, to be presented at AD/PD™ 2024, show promising results in non-human primates and mice. Voyager plans to file an IND for VY-TAU01 in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
-
News
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
Rhea-AI Summary
Voyager Therapeutics, Inc. will present at the Oppenheimer Life Sciences Conference on February 14, 2024. The webcast of the presentation can be accessed from the Investors section of Voyager's website. Chief Financial Officer Peter Pfreundschuh will be presenting at 11:20 a.m. ET. A replay of the webcast will be available on the company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
conferences
-
News
Voyager Therapeutics Announces Pricing of Public Offering
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announces the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and pre-funded warrants to purchase an aggregate of 3,333,333 shares of common stock at a public offering price of $8.999 per pre-funded warrant, for aggregate gross proceeds of approximately $100 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.36%
Tags
offering
News
Voyager Therapeutics Announces Proposed Public Offering
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced a public offering of $100 million of shares of its common stock. The company also expects to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares. The net proceeds will be used for advancing its neurogenetic medicines and various clinical and preclinical development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.36%
Tags
offering
Stock VYGR logo
Voyager Therapeutics Inc

Nasdaq:VYGR

VYGR Rankings

#3126 Ranked by Market Cap
#801 Ranked by Stock Gains
N/A Ranked by Dividends

VYGR Stock Data

457.75M
36.94M
17.29%
49%
6.13%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About VYGR

voyager therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (cns). voyager is committed to advancing the field of aav (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. the company’s initial pipeline is focused on cns diseases in dire need of effective new therapies, including parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (als), and friedreich’s ataxia. founded by scientific and clinical leaders in the fields of aav gene therapy, expressed rna interference and neuroscience, voyager therapeutics was launched in 2014 with funding from leading life sciences investor third rock ventures and is headquartered in cambridge, mass. for more information, please visit www.voyagertherapeutics.com.